Trends in Morbidity and Mortality after Hepatic Resection for Hepatocellular Carcinoma: An Institute’s Experience with 625 Patients
Akinobu Taketomi(Hokkaido University), Yoshihiko Maehara(Kyushu University), Shinji Itoh(Kyushu University), Norifumi Harimoto(National Kyushu Medical Center), Dai Kitagawa(Kyushu University), Mitsuo Shimada(Tokushima University), Tomonobu Gion(Kyushu University), Yo‐ichi Yamashita(Kumamoto University), Ken Shirabe(Gunma University)
Cited by 168
Related Papers
Clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2017 (4th JSH‐HCC guidelines) 2019 update
|Hepatology Research|2019|539
Randomized clinical trial of adjuvant gemcitabine chemotherapy <i>versus</i> observation in resected bile duct cancer
|British journal of surgery|2018|401
Interleukin‐6/<scp>STAT</scp>3 signaling as a promising target to improve the efficacy of cancer immunotherapy
|Cancer Science|2017|295
Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2021 version (5th JSH‐HCC Guidelines)
|Hepatology Research|2023|281
Genome-wide Association Study Identifies TNFSF15 and POU2AF1 as Susceptibility Loci for Primary Biliary Cirrhosis in the Japanese Population
|The American Journal of Human Genetics|2012|272